Bionoid Pharma, Inc.
BINP · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | – | 100% | -290.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | 559% | -1,487.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | -$0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | 530.2% | -1,504.7% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | 611.2% | -1,677.4% |
| EPS | -0.004 | -0.005 | -0.002 | -0.003 |
| % Growth | 15.2% | -206.7% | 55.9% | – |
| EPS Diluted | -0.004 | -0.005 | -0.002 | -0.003 |
| Weighted Avg Shares Out | 54 | 54 | 54 | 54 |
| Weighted Avg Shares Out Dil | 54 | 54 | 54 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | -$0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $1 | -$0 |
| % Margin | – | – | -2,689.1% | -86.9% |